Harbour BioMed Reports Promising Phase II Study Outcomes of HBM4003 with Tislelizumab for mCRC Treatment Harbour BioMed reveals encouraging Phase II results for HBM4003 combined with tislelizumab in patients with MSS mCRC, showcasing potential in novel treatments.

Harbour BioMed Reports Promising Phase II Study Outcomes of HBM4003 with Tislelizumab for mCRC Treatment #None #Harbour_BioMed #Tislelizumab #HBM4003

Harbour BioMed to Showcase HBM4003 and Tislelizumab Trial Results at ESMO 2025 Harbour BioMed announces it will present Phase II trial data for HBM4003 and Tislelizumab at ESMO 2025, focusing on MSS mCRC treatment.

Harbour BioMed to Showcase HBM4003 and Tislelizumab Trial Results at ESMO 2025 #None #Harbour_BioMed #Tislelizumab #HBM4003